 |
Европейская академия
|
| В начало | Энциклопедия ЕАЕН | |
Энциклопедия Европейской академии естественных наук |
||
Quanjun Wang
Quanjun Wang, Ph.D., is currently the Chief Executive Officer and Chief Scientist of SAFE Pharmaceutical Group, and the Vice President of Suzhou Institute of Materia Medica, Chinese Academy of Sciences.
Dr. Quanjun Wang has been engaged in non-clinical evaluation research on innovative drugs (pharmacology and toxicology), and made outstanding contributions. For the first time in China, he proposed and established the concept and method of "discovery toxicology" and the "early toxicity optimization screening" technology system, which have been successfully applied to the optimization screening research of innovative drugs. He is the first scholar in China to carry out toxicological metabolomics research and establish a toxicological metabolomics technology research system, and has established a drug evaluation strategy based on toxicological mechanisms, which has shortened the species prediction distance, thus forming a new model of "whole-process drug evaluation research".
He is also one of the first scholars in China to carry out non-clinical evaluation research on cell and gene therapy (CGT) products. From different aspects such as animal models, analysis techniques and outcome prediction, he has carried out non-clinical evaluation research on cell and gene therapy products, and has completed more than 60 non-clinical evaluation studies of cell and gene therapy products, which have been successfully applied to the China NMPA and the US FDA Center for Drug Evaluation. Further, he is the editor-in-chief of China's first monograph on "Non-clinical Evaluation of Cell Therapy and Gene Therapy Products".
He also serves as the Executive Director and Deputy Secretary-General of the Chinese Society of Toxicology; the Chairman of the Drug Toxicology and Safety Evaluation Committee of the Chinese Society of Toxicology; the Director of Chinese Pharmaceutical Association; the Vice Chairman of the Drug Toxicology Committee of the Chinese Pharmacological Society; the Vice Chairman of Antibody Engineering Society of Chinese Society of Biotechnology; the Vice Chairman of the Mutagenicity Committee of the Chinese Environmental Mutagen Society; the Vice Chairman of the Cell and Gene Therapy Drug Quality Research Committee of China Quality Association for Pharmaceuticals; the Member of the Regulatory Science and International Standards Committee of the Chinese Pharmaceutical Association; and the Member of the Drug Research and Development Committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA).
| Энциклопедия ЕАЕН |